Students Classroom

Ophthalmology Grand Rounds

July 6, 2022 | 7–8 a.m. MCW_Icons_Make_An_Appointment_Green iCAL

Development of an Inducible Gene Therapy Treatment for Open Angle Glaucoma

Daniel M. Lipinski, MSc, DPhil
Associate Professor

In this session you will learn: Open angle glaucoma and related optic neuropathies are a leading cause of irreversible blindness worldwide and are characterized by progressive loss of retinal ganglion cells, atrophy of the optic nerve and severe visual field deficits. The major risk factor for open angle glaucoma is increased intraocular pressure (IOP) resulting from an imbalance between aqueous humor production and outflow. As such, the standard clinical therapy is to reduce IOP through a combination of topical drug administration and surgery. The major clinical challenge is that due to the largely asymptomatic (i.e. non-painful) nature of the disease and the need to maintain a lifelong daily treatment regimen, patient compliance is extremely poor, often leading to the development of sight threatening complications, even in patients diagnosed early. In this talk we will present our progress towards the development of an alternative therapeutic approach using gene therapy to permanently lower IOP in open angle glaucoma following a single therapeutic intervention.

Event Location

  • Webex